Medicenna Therapeutics reports developments as a clinical-stage immunotherapy company developing proprietary Superkines for cancer, autoimmune and inflammatory diseases. Recurring updates center on MDNA11, a long-acting IL-2 Superkine; MDNA113, a tumor-targeted and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine; and bizaxofusp, formerly MDNA55, an IL-4 Empowered Superkine studied in glioblastoma.
Company news also includes clinical and preclinical data presentations at oncology and healthcare conferences, corporate and financial updates, collaborations around investigator-initiated trials, and governance changes such as board and medical leadership appointments.
Medicenna (OTCQX: MDNAF; TSX: MDNA) will host a live webinar on December 10, 2025 at 08:30 AM ET to discuss updated clinical data from the ABILITY-1 Phase 1/2 study evaluating MDNA11 as a monotherapy and in combination with pembrolizumab. The event features presentations by company management and the presenting Principal Investigator, followed by commentary from key opinion leaders and live Q&A.
Presenters include Dr. Fahar Merchant (President and CEO), Dr. Arash Yavari (Director of Clinical Strategy) and Dr. André Mansinho (presenting Principal Investigator). Registration is required and a replay will be available on Medicenna’s website after the event.
Medicenna (OTCQX: MDNAF, TSX: MDNA) reported Q2 fiscal 2026 results and a corporate update on Nov 13, 2025. Key clinical milestones include an MDNA11 data presentation at ESMO IO Congress on Dec 10, 2025 and a randomized neoadjuvant NEO-CYT trial in Italy (up to 12 centres) testing MDNA11 with nivolumab ± ipilimumab. MDNA113 is in non-human primate studies with IND-enabling work planned H1 2026 and a first-in-human trial targeted H2 2026. Six patents were issued or allowed across US, Japan, Canada and Australia. Cash was $15.7M, providing runway into at least mid-2026.
Medicenna (OTCQX: MDNAF) announced a randomized, investigator‑initiated neoadjuvant trial named NEO-CYT to test MDNA11 with nivolumab ± ipilimumab in high‑risk, surgically resectable Stage III melanoma.
The study is sponsored by Fondazione Melanoma Onlus at Istituto Nazionale Tumori ‘G. Pascale’; Medicenna will supply study drug. Primary endpoint is Major Pathologic Response (MPR). Company noted prior deep, durable responses in the ongoing ABILITY‑1 study and expects cash & equivalents to fund operations into at least mid‑2026.
Medicenna (OTCQX: MDNAF, TSX: MDNA) will present updated clinical data for MDNA11 from the Phase 1/2 ABILITY-1 study at the ESMO Immuno-Oncology Congress 2025 in London on December 10-12, 2025. The presentation by Dr. André Mansinho covers an interim analysis of MDNA11 as a monotherapy and in combination with pembrolizumab in advanced solid tumors.
Presentation title: ABILITY-1, a phase 1/2 of MDNA11, a next-generation IL-2 agonist, alone or with pembrolizumab in advanced solid tumors: interim analysis. A copy of the presentation will be posted on the company’s Events and Presentations page after the congress.
Medicenna Therapeutics (TSX: MDNA, OTCQX: MDNAF) announced participation in three upcoming investor and industry events in late 2025 to present its Superkines pipeline and engage partners and investors.
- Planet MicroCap Showcase: TORONTO 2025 – Oct 22, 2025; presentation and one-on-ones; 1:30 PM ET; webcast available.
- BIO-Europe 2025 – Nov 3–5, 2025; Vienna; one-on-one partnering meetings.
- Oppenheimer Miami Oncology Summit – Nov 6, 2025; Miami; panels and networking.
The events are described as opportunities to highlight ongoing clinical trials, discuss the company’s immunotherapy programs, and meet potential partners and investors.
Medicenna Therapeutics (OTCQX: MDNAF), a clinical-stage immunotherapy company, announced its participation in the upcoming ROTH 4th Annual Healthcare Opportunities Conference. The event will take place on October 8-9, 2025 at the Metropolitan Club in New York City.
Dr. Fahar Merchant, President and CEO of Medicenna, will engage in one-on-one and small group meetings with institutional investors, providing detailed insights into the company's development of Superkines for treating cancer, autoimmune, and inflammatory diseases.
Medicenna Therapeutics (OTCQX: MDNAF), a clinical-stage immunotherapy company specializing in Superkines development, held its annual shareholders meeting on September 25, 2025. The meeting saw a 55.75% turnout of issued and outstanding common shares, with all nominated directors successfully elected with overwhelming support, each receiving over 98.8% approval.
Notable changes include Dr. John H. Sampson's departure from the board, though he will continue as a clinical advisor. The election results demonstrated strong shareholder confidence, with key figures like Dr. Fahar Merchant and Ms. Karen Dawes receiving 99.25% and 99.35% of votes respectively.
Medicenna Therapeutics (OTCQX:MDNAF), a clinical-stage cancer immunotherapy company specializing in Superkines development, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
Dr. Fahar Merchant, President and CEO, will deliver a presentation on September 9th, 2025, at 2:30 PM EST at the Lotte New York Palace Hotel. The presentation will be available via webcast, with a 90-day replay period accessible through Medicenna's investor relations website.
Medicenna Therapeutics (OTCQX:MDNAF) reported its Q1 fiscal 2026 results, highlighting significant progress in its immunotherapy pipeline. The company ended Q1 with $20.5 million in cash, providing runway into mid-2026. Operating costs increased to $5.5 million, up from $4.0 million year-over-year, with net loss at $0.06 per share.
Key clinical achievements include promising MDNA11 results, with 30-50% response rates in high-dose patients and complete responses in pancreatic and melanoma cancers. The Phase 1/2 ABILITY-1 trial remains on track for top-line data in H2 2025. The company's IP portfolio expanded to 86 granted patents, strengthening its commercial potential.
R&D expenses increased to $4.2 million from $2.8 million, primarily due to ABILITY-1 Study expansion, while G&A expenses remained stable at $1.3 million.
Medicenna Therapeutics (OTCQX: MDNAF) has strengthened its intellectual property portfolio with five newly granted patents for its IL-2 and IL-4 Superkine platforms. The patents, which expire between 2033 and 2040, cover composition, formulation, combination, use, and therapeutic applications across major global markets.
Key patents include protection for MDNA11 in combination with anti-PD-1 antibodies and a novel formulation of bizaxofusp (MDNA55) for brain cancer treatment. The company's global IP portfolio now includes 86 granted or allowed patents, supporting their clinical pipeline in oncology and autoimmune diseases.